TOCA vs. RPHM, CARM, ANEB, IMMX, RMTI, KZR, EQ, CASI, DRRX, and LEXX
Should you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Reneo Pharmaceuticals (RPHM), Carisma Therapeutics (CARM), Anebulo Pharmaceuticals (ANEB), Immix Biopharma (IMMX), Rockwell Medical (RMTI), Kezar Life Sciences (KZR), Equillium (EQ), CASI Pharmaceuticals (CASI), DURECT (DRRX), and Lexaria Bioscience (LEXX). These companies are all part of the "medical" sector.
Reneo Pharmaceuticals (NASDAQ:RPHM) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
Tocagen has higher revenue and earnings than Reneo Pharmaceuticals. Reneo Pharmaceuticals is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.
Reneo Pharmaceuticals presently has a consensus price target of $11.01, suggesting a potential upside of 547.79%. Given Tocagen's higher probable upside, equities analysts clearly believe Reneo Pharmaceuticals is more favorable than Tocagen.
In the previous week, Reneo Pharmaceuticals had 3 more articles in the media than Tocagen. MarketBeat recorded 3 mentions for Reneo Pharmaceuticals and 0 mentions for Tocagen. Tocagen's average media sentiment score of 1.52 beat Reneo Pharmaceuticals' score of 0.00 indicating that Reneo Pharmaceuticals is being referred to more favorably in the media.
Reneo Pharmaceuticals has a net margin of 0.00% compared to Reneo Pharmaceuticals' net margin of -176,433.34%. Tocagen's return on equity of -67.76% beat Reneo Pharmaceuticals' return on equity.
91.0% of Reneo Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.4% of Tocagen shares are owned by institutional investors. 17.9% of Reneo Pharmaceuticals shares are owned by company insiders. Comparatively, 10.9% of Tocagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Reneo Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.
Tocagen received 223 more outperform votes than Reneo Pharmaceuticals when rated by MarketBeat users. Likewise, 66.03% of users gave Tocagen an outperform vote while only 57.14% of users gave Reneo Pharmaceuticals an outperform vote.
Summary
Reneo Pharmaceuticals beats Tocagen on 10 of the 15 factors compared between the two stocks.
Get Tocagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
